# Ocular Melanoma UK Generated by Yoast SEO v28.2, this is an llms.txt file, meant for consumption by LLMs. ## Pages - [About us](https://omuk.org/about-us/) - [Contact Us](https://omuk.org/contact-us/) - [Privacy Notice](https://omuk.org/privacy-policy/) - [Shop](https://omuk.org/support-us/shop/) - [Homepage](https://omuk.org/) - [Help And Support](https://omuk.org/help-and-support/) - [Support Us](https://omuk.org/support-us/) - [Resources](https://omuk.org/resources/) ## Posts - [Tebentafusp approved for eligible patients with advanced uveal melanoma in Scotland](https://omuk.org/tebentafusp-approved-for-eligible-patients-with-advanced-uveal-melanoma-in-scotland/) - [CHEMOSAT update: NICE draft guidance and NHS England routine funding proposal](https://omuk.org/chemosat-update-nice-draft-guidance-and-nhs-england-routine-funding-proposal/) - [Rare cancer patients warn delays still risk lives despite cancer plan pledges\.](https://omuk.org/rare-cancer-patients-warn-delays-still-risk-lives-despite-cancer-plan-pledges/) - [Ocular Melanoma UK Statement on Access to Chemosaturation Treatment](https://omuk.org/ocular-melanoma-uk-statement-on-access-to-chemosaturation-treatment/) - [Ocular Melanoma UK says NHS inaction is costing lives as patients left unable to access recommended cancer treatment](https://omuk.org/nhs-england-rare-cancer-patientsocular-melanoma-uk-says-nhs-inaction-is-costing-lives-as-patients-left-unable-to-access-recommended-cancer-treatmentnhs-england-rare-cancer-patients/) ## Donation Forms - [Support the OMUK Wellbeing Programme](https://omuk.org/donations/support-the-omuk-wellbeing-programme/) - [Christmas Appeal 2025: Help Ensure No One Faces Ocular Melanoma Alone](https://omuk.org/donations/christmas-appeal-2025-help-ensure-no-one-faces-ocular-melanoma-alone/) - [In Loving Memory Of Brian Chystal](https://omuk.org/donations/givewp-donation-form/) - [Donation Form](https://omuk.org/donations/givewp-donation-form-2/) ## Clinical trials - [Different Doses of BI\-1607 in Combination With Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors \- NCT04336241](https://omuk.org/clinical-trial/study-of-rp2-monotherapy-and-rp2-in-combination-with-nivolumab-in-patients-with-solid-tumors-nct04336241/) - [ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors \(ACTengine\) \- NCT03686124](https://omuk.org/clinical-trial/actengine-ima203-ima203cd8-as-monotherapy-or-in-combination-with-nivolumab-in-recurrent-and-or-refractory-solid-tumors-actengine-nct03686124/) - [Study of Roginolisib in UM Patients \(OCULE\-01\) \- NCT06717126](https://omuk.org/clinical-trial/study-of-roginolisib-in-um-patients-ocule-01-nct06717126/) - [Study Assessing MTD, Safety, Tolerability, PK and Anti\-tumor Effects of LNS8801 alone and with Pembrolizumab \- NCT04130516](https://omuk.org/clinical-trial/lns8801-with-and-without-pembrolizumab/) - [A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors \- NCT07070232](https://omuk.org/clinical-trial/a-clinical-study-to-test-if-an-investigational-treatment-called-bnt326-is-safe-and-potentially-beneficial-when-used-alone-or-in-combination-with-other-investigational-treatments-such-as-bnt327-for-pe/) ## Resources - [Resource name test](https://omuk.org/resource/resource-name-test/) - [Three\-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma\.](https://omuk.org/resource/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/) ## Products - [Ocular Melanoma UK Sporty T\-shirt](https://omuk.org/product/ocular-melanoma-uk-t-shirt/): Unisex Ocular Melanoma UK branded sporty t\-shirt\. Crafted from a lightweight Neoteric fabric that wicks away sweat, this t\-shirt will beat the heat\. 100% polyester\. \